Duchenne Muscular Dystrophy (DMD) Treatment Market Size, Share, Opportunities, COVID 19 Impact, And Trends By Tests (Blood Test, Molecular, Genetic Testing, Electromyography, Muscle Biopsy), By Treatment (Physical Therapy, Orthopedic Devices, Steroids, Others), And By Geography - Forecasts From 2019 To 2024
- Published : Jun 2021
- Report Code : KSI061612301
- Pages : 110
Offered with this report
Market Data and Estimates in Excel
2 Months of Post Sale Analyst Support
Requirement Specific Customization
The Duchenne Muscular Dystrophy (DMD) treatment market is estimated to be valued at US$981.367 million in 2018 and is expected to grow steadily during the forecast period. Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder caused by the mutation of the DMD gene, which is responsible for making a protein called dystrophin causing progressive muscle degeneration. At present, there is no cure for the disease, certain research strategies are being worked upon, however, the treatment is provided for the mitigation of disease symptoms.
The growing incidence of rare diseases, rising R&D investments, and growing adoption of genetic testing worldwide are some of the major drivers driving the growth of the Duchenne muscular dystrophy (DMD) treatment market during the forecast period. Furthermore, growing awareness regarding self-care and self-management resulting in early disease detection will help in disease management in an efficient manner leading to sustainable market growth in the near future and beyond. The prevalence of Duchenne and Becker muscular dystrophy (DBMD) among Non-Hispanic blacks was lower than the prevalence among Hispanics and Non-Hispanic whites (Centers for Disease Control and Prevention, CDC). Thus, owing to high disease prevalence, North America and Europe are expected to hold a significant market share globally.
This research study examines the current market trends related to demand, supply, and sales, in addition to recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases, and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top-down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the Duchenne muscular dystrophy (DMD) treatment value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics for providing a faster and more efficient understanding of the Duchenne muscular dystrophy (DMD) treatment market.
Major industry players profiled as part of the report are Pfizer Inc., Sarepta Therapeutics, Inc., ReveraGen BioPharma, Inc., PTC Therapeutics, and NIPPON SHINYAKU CO., LTD. among others.
Duchenne Muscular Dystrophy (DMD) Treatment Market Scope:
| Report Metric | Details |
| Market size value in 2018 | US$981.367 million |
| Growth Rate | CAGR of during the forecast period |
| Base year | 2018 |
| Forecast period | 2019–2024 |
| Forecast Unit (Value) | USD Million |
| Segments covered | Tests, Treatment, And Geography |
| Regions covered | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies covered | Pfizer Inc., Sarepta Therapeutics, Inc., ReveraGen BioPharma, Inc., PTC Therapeutics, NIPPON SHINYAKU CO., LTD., ITALFARMACO S.p.A., FibroGen, Inc., DAIICHI SANKYO COMPANY, LIMITED., Solid Biosciences Inc. |
| Customization scope | Free report customization with purchase |
Segmentation
The Duchenne muscular dystrophy (DMD) treatment market has been analyzed through the following segments:
By Tests
Blood Test
Molecular Genetic Testing
Electromyography
Muscle Biopsy
By Treatment
Physical Therapy
Orthopedic Devices
Steroids
Others
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
Israel
Others
Asia Pacific
China
Japan
South Korea
India
Others
Frequently Asked Questions (FAQs)
Q1. What is the size of the Duchenne muscular dystrophy treatment market?
A1. The Duchenne Muscular Dystrophy (DMD) treatment market is estimated to be valued at US$981.367 million in 2018.
Q2. Who are the major players in Duchenne muscular dystrophy treatment?
A2. Major industry players profiled as part of the report are Pfizer Inc., Sarepta Therapeutics, Inc., ReveraGen BioPharma, Inc., PTC Therapeutics, and NIPPON SHINYAKU CO., LTD. among others.
Q3. How is the global Duchenne muscular dystrophy treatment market segmented?
A3. The Duchenne muscular dystrophy treatment market has been segmented by tests, treatment, and geography.
Q4. What factors are anticipated to drive Duchenne muscular dystrophy treatment growth?
A4. The growing incidence of rare diseases, rising R&D investments, and growing adoption of genetic testing worldwide are some of the major drivers driving the growth of the Duchenne muscular dystrophy treatment market during the forecast period.
Q5. Which region holds the largest market share in Duchenne muscular dystrophy treatment?
A5. North America and Europe are expected to hold a significant market share globally.
1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Overview and Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Prevalence
4.5.1. By age group
4.5.2. By gender
4.5.3. By region
4.6. Product Pipeline
4.7. Innovations
5. DUCHENNE MUSCULAR DYSTROPHY (DMD) TREATMENT MARKET BY TESTS
5.1. Blood Test
5.2. Molecular Genetic Testing
5.3. Electromyography
5.4. Muscle Biopsy
6. DUCHENNE MUSCULAR DYSTROPHY (DMD) TREATMENT MARKET BY TREATMENT
6.1. Physical Therapy
6.2. Orthopedic Devices
6.3. Steroids
6.4. Others
7. DUCHENNE MUSCULAR DYSTROPHY (DMD) TREATMENT MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Others
8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Pfizer Inc.
9.2. Sarepta Therapeutics, Inc.
9.3. ReveraGen BioPharma, Inc.
9.4. PTC Therapeutics
9.5. NIPPON SHINYAKU CO.,LTD.
9.6. ITALFARMACO S.p.A.
9.7. FibroGen, Inc.
9.8. DAIICHI SANKYO COMPANY, LIMITED.
9.9. Solid Biosciences Inc.
LIST OF FIGURES
LIST OF TABLES
Sarepta Therapeutics, Inc.
ReveraGen BioPharma, Inc.
PTC Therapeutics
NIPPON SHINYAKU CO., LTD.
ITALFARMACO S.p.A.
FibroGen, Inc.
DAIICHI SANKYO COMPANY, LIMITED.
Solid Biosciences Inc.
Related Reports
| Report Name | Published Month | Get Sample PDF |
|---|---|---|
| Hepatitis Diagnostic and Treatment Market Size: Report, 2023 - 2028 | Mar 2023 | |
| Endocrine Testing Market Size & Share: Industry Report, 2024-2029 | Apr 2024 | |
| Coagulation Testing Market Size: Industry Report, 2022-2027 | Feb 2022 | |
| Blood Glucose Test Strips Market Size & Share: Report, 2022-2027 | Apr 2022 | |
| Laboratory Automation Market Size, Share & Analysis: 2021 - 2026 | Jul 2021 |